Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHORT-LGV
NCT07767422Phase 2Not yet recruiting
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Sep 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxycycline in lymphogranuloma venereum (LGV), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Microbiological cure rate of a 7-day course of doxycycline for asymptomatic anal LGV at 4 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
doxycycline
03
Conditions
lymphogranuloma venereum (LGV)
Beyond the preview
Go deeper on NCT07767422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07767422.